The numbers tell two stories about Oracle right now, and both are true. One is a stock that just delivered its strongest weekly gain in recent memory, closing Friday at EUR 127.10 after climbing 12.84 percent in seven days. The other is a company whose credit default swaps have hit record levels, whose shares remain 56.89 percent below their September 10, 2025 peak, and whose founder watched his personal fortune shrink by roughly $213 billion in a matter of weeks.
Reconciling those realities is the central challenge for anyone holding the stock.
The bull case is intact — on the surface
Oracle’s fourth fiscal quarter, which ended May 31, produced revenue of $19.18 billion, up 20.6 percent year over year. Adjusted earnings per share came in at $2.11, comfortably ahead of market expectations. The cloud backlog stands at a record $638 billion, fueled by signals from Microsoft, Amazon, and Samsung that demand for AI infrastructure remains robust.
The company has also been busy converting partnerships into products. Oracle Interconnect for AWS reached general availability on July 29, and the AI Database@AWS offering is expanding into new regions including Stockholm and San Jose. Google’s Gemini models are being integrated into Oracle Fusion Applications and NetSuite. CACI has signed on for HRIT modernization work tied to the US Office of Personnel Management contract, and Oracle Health is extending into Ontario hospitals.
The catalysts for this week’s bounce went beyond company-specific news. President Trump’s decision to call off military strikes against Iran and announce new negotiations provided a broad market tailwind that lifted Oracle along with everything else.
The bear case is equally visible
Strip away the weekly noise and the picture darkens considerably. Oracle remains 16.79 percent below its 200-day moving average of EUR 152.74, a technical signal that the long-term downtrend has not broken. The stock is still down 23.53 percent year to date and has lost 40.64 percent over the past twelve months. Even after rallying 26.14 percent off its 52-week low of EUR 100.76 from July 28, the shares trade nowhere near the levels investors saw a year ago.
The deeper concern is financial. Oracle’s massive capital expenditures on AI data centers have pushed its credit default swaps to record levels, signaling that the market sees rising risk in the company’s ability to service its debt. This is part of a broader industry phenomenon — tech companies are flooding the bond market to fund AI infrastructure — but Oracle is increasingly viewed as one of the names most vulnerable to a ratings downgrade if the “AI debt fatigue” that has gripped credit investors spreads further.
Should investors sell immediately? Or is it worth buying Oracle?
The analyst community reflects this divergence. UBS cut its price target on August 3 from $285 to $245, maintaining a “Buy” rating while flagging concerns about AI infrastructure spending, return on capital, credit market conditions, and Oracle’s dependence on OpenAI. The same day, Guggenheim reaffirmed its “Buy” with a $400 target after meeting with Oracle management. The gap between those two figures — $155 — captures just how uncertain the risk picture has become. A broader consensus of recent months clusters between $248 and $262, though that figure blends older and fresher assessments.
Insider selling — and a founder’s side bet
Institutional investors have been split in their response. Several funds, including Teamwork Financial Advisors, added to their positions during the second quarter. Vice Chairman Jeffrey Henley, meanwhile, sold 400,000 shares on June 24 at an average price of $159.16. Context matters here: the sale was executed through a Rule 10b5-1 automated trading plan established on January 2, meaning the transaction was scheduled months in advance rather than reflecting a sudden loss of confidence.
Larry Ellison’s personal financial situation is more complicated. His Oracle-linked wealth reportedly fell from a peak near $388 billion to roughly $175 billion, a decline of about $213 billion, as the stock tumbled roughly a third in 2026 and nearly half since early June. Separately, Ellison has provided an irrevocable personal guarantee of $40.4 billion in equity financing for the Paramount Skydance merger with Warner Bros. Discovery. The Justice Department cleared that deal in June, and the EU Commission followed on July 22 with conditions on film distribution in Europe. Twelve state attorneys general, led by California, sued to block the merger, and a federal judge temporarily halted it. On July 24, the parties agreed the deal cannot close before June 1, 2027, or five days after a ruling on the merits.
That legal saga is not an operational risk for Oracle shareholders, but it illustrates how deeply Ellison’s personal exposure is now tied to leveraged, high-risk ventures — a pattern that mirrors the company’s own balance sheet trajectory.
What comes next
The next test arrives September 7, when Oracle reports fiscal first-quarter 2027 results. The consensus calls for earnings per share of $1.77 on revenue of $19.52 billion. In October, the Oracle AI World conference runs from the 25th through the 28th, offering another showcase for the company’s AI strategy.
The analyst consensus price target of EUR 214.63 implies nearly 69 percent upside from current levels, but that figure assumes Oracle can manage its debt burden while translating operational strength into sustainable profitability. The stock’s RSI of 56.1 suggests stabilization rather than a breakout. Until Oracle can reclaim its long-term moving averages on a sustained basis, this remains a recovery bet with elevated risk — one where the debt question can overshadow the growth story at any moment.
Ad
Oracle Stock: Buy or Sell?! New Oracle Analysis from August 8 delivers the answer:
The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 8.
Oracle: Buy or sell? Read more here...
